On May 4, 2020, Anixa Biosciences and partner OntoChem, announced they had identified its first therapeutic candidate against Covid-19, and has advanced the compound into biological testing. This is the first therapeutic candidate identified from the strategic partnership established by Anixa and OntoChem to evaluate over 1.2 billion molecules through an in silico study to identify potential therapies for patients infected by SARS-CoV-2, the virus that causes Covid-19.